Why Is Plus Therapeutics Stock Rising After Data Presentation From Brain Tumor Trial?

Plus Therapeutics Inc's PSTV shares are moving after presenting data from a Phase 1 ReSPECT trial evaluating Rhenium-186 NanoLiposome (186RNL) in recurrent glioblastoma (GBM).
The data was presented at the American Association of Neurological Surgeons Annual Scientific Meeting.
Administration of 186RNL was well tolerated in adult patients at significantly higher doses than with standard treatment modalities such as external beam radiation therapy (EBRT).
Related: Highlights Of Preclinical Data For Targeted Cancer Radiation Therapy.
The mean dose of 186RNL when coverage was 75% or greater (n=10) was 392 Gy (CI 306 – 478).
No dose-limiting toxicity or serious adverse events were observed (n=18).
In addition, PSTV plans to evaluate 186RNL in a two-part Phase 1 trial in pediatric brain tumor patients.
Part one (n=18) will determine the maximum feasible dose of 186RNL with the tumor diameter limited to four centimeters and a volume of 34 milliliters.
Part two (n=39) will independently evaluate 186RNL across three different cohorts based on specific disease diagnoses.
The study's primary endpoint will be the overall response rate.
Secondary endpoints will include progression-free survival and overall survival.
Patient enrollment will begin by mid-2022.
Price Action: PSTV shares are up 19.6% at $2.32 on heavy volume during the premarket session on the last check Monday.